Supplementary Table 1 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Authors :: Hani Gabra
Tarek M. Meniawy
Prashanth Gopalakrishna
Euan A. Stronach
Eleni Frangou
Michelle DeSilvio
Alla S. Lisyanskaya
Jeffrey C. Goh
Marcia Hall
Agnieszka Michael
Shirley Wong
Linda Mileshkin
Anne L. Hamilton
Sarah P. Blagden
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Summary of exposure to afuresertib, paclitaxel and carboplatin

Full Text Access

Tools